Stockreport

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Ironwood Pharmaceuticals, Inc. - Class A  (IRWD) 
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.ironwoodpharma.com
PDF - Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million -- [Read more]